The progress and prospects of routine prophylactic antiviral treatment in hepatitis B-related hepatocellular carcinoma

被引：22

作者：

Jiang, Enze ^{[1
]}

Shangguan, Anna Junjie ^{[2
]}

Chen, Shuangshuang ^{[3
]}

Tang, Lin ^{[1
]}

Zhao, Shuang ^{[1
]}

Yu, Zhenghong ^{[1
]}

机构：

[1] Nanjing Univ, Sch Med, Dept Med Oncol, Jinling Hosp, Nanjing, Jiangsu, Peoples R China

[2] Northwestern Univ, Weinberg Coll Arts & Sci, Evanston, IL USA

[3] Nanjing Univ Chinese Med, Jinling Hosp, Dept Med Oncol, Nanjing, Jiangsu, Peoples R China

来源：

CANCER LETTERS | 2016年 / 379卷 / 02期

关键词：

Antiviral treatment; Hepatocellular carcinoma; Hepatitis B virus; CLINICAL-PRACTICE GUIDELINES; LOCAL ABLATIVE THERAPY; VIRUS REACTIVATION; LONG-TERM; TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; LIVER RESECTION; NUCLEOTIDE/NUCLEOSIDE ANALOGS; NUCLEOS(T)IDE ANALOGS; CURATIVE RESECTION;

D O I：

10.1016/j.canlet.2015.07.016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Liver cancer is a common cancer and a leading cause of cancer-related deaths. Among all types of primary liver cancers, hepatocellular carcinoma (HCC) is the major histological subtype, and hepatitis B virus (HBV) infection is the leading cause of HCC. Treatments for hepatitis B related HCC include hepatectomy, liver transplantation, transarterial chemoembolization (TACE), ablative therapy, and Sorafenib treatment. However, HBV reactivation can occur in patients who receive these treatments, resulting in poor clinical outcomes. However, prophylactic antiviral treatment in patients with hepatitis B-related HCC, can reduce the copies of HBV DNA, prevent HBV reactivation, reduce hepatic inflammation, reverse liver fibrosis, decrease tumor recurrence and metastasis, and extend survival time. Prophylactic antiviral treatment should be routinely performed as an important adjuvant therapy in HBV-related HCC patients. Published by Elsevier Ireland Ltd.

引用

页码：262 / 267

页数：6

共 86 条

[1]

[Anonymous], HEP B FACT SHEET 204

[2] Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma [J].

Arzumanyan, Alla ;

Reis, Helena M. G. P. V. ;

Feitelson, Mark A. .

NATURE REVIEWS CANCER, 2013, 13 (02) :123-135

[3]

BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO

[4]

2-J

[5]

BEASLEY RP, 1981, LANCET, V2, P1129

[6] Impact of Antiviral Therapy on the Survival of Patients After Major Hepatectomy for Hepatitis B Virus-Related Hepatocellular Carcinoma [J].

Chan, Albert C. Y. ;

Chok, Kenneth S. H. ;

Yuen, Wai Key ;

Chan, See Ching ;

Poon, Ronnie T. P. ;

Lo, Chung Mau ;

Fan, Sheung Tat .

ARCHIVES OF SURGERY, 2011, 146 (06) :675-681

[7]

Chang CH, 2013, MED CARE, V51, P908, DOI 10.1097/MLR.0b013e3182a502ba

[8]

Chen Li-Ping, 2012, World J Virol, V1, P174, DOI 10.5501/wjv.v1.i6.174

[9] A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma [J].

Chen, MS ;

Li, JQ ;

Zheng, Y ;

Guo, RP ;

Liang, HH ;

Zhang, YQ ;

Lin, XJ ;

Lau, WY .

ANNALS OF SURGERY, 2006, 243 (03) :321-328

[10] Potent hepatitis B surface antigen response to treatment of hepatitis-B-e-antigen-positive chronic hepatitis B with α-interferon plus a nucleos(t)ide analog [J].

Chen, Xinyue ;

Cao, Zhenhuan ;

Liu, Yali ;

Zhang, Hongwei ;

Zhang, Yonghong ;

Ma, Lina ;

Jin, Yi ;

Yu, Haibin ;

Ma, Bing ;

Zheng, Yanhong ;

Wu, Hao .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (03) :481-486

← 1 2 3 4 5 6 7 8 9 →